Giiant Pharma is a technology company.
Giiant Pharma has raised $12.0M across 1 funding round.
Giiant Pharma has raised $12.0M in total across 1 funding round.
Giiant Pharma has raised $12.0M in total across 1 funding round.
Giiant Pharma's investors include Amplitude VC, Mott Family Capital, OrbiMed.
Giiant Pharma is a Montreal-based preclinical-stage biotech company developing gut-restricted, small-molecule therapeutics for inflammatory bowel diseases (IBD), such as ulcerative colitis.[1][2][3][5] Founded by former Merck Frosst scientists, it builds the Precision Delivery platform, which uses gut microbiota to bioactivate orally administered prodrugs like GT-2108—a colon-specific PDE4 inhibitor—delivering high local concentrations with minimal systemic exposure to improve tolerability and safety.[4][5] The company serves IBD patients suffering from moderate-to-severe symptoms, addressing limitations of existing treatments by enabling precise, tissue-specific action in the lower GI tract.[3][4][5] In 2023, Giiant raised $11 million in seed funding from investors including Amplitude Ventures, Genesys Capital, and AmorChem, fueling its IND-enabling preclinical program and pipeline expansion.[4]
Giiant Pharma was founded in 2010 by two former Merck Frosst scientists—repeat entrepreneurs with deep biotech expertise—who originated the Precision Delivery technology from their prior research.[1][2][3] Dr. Elizabeth Kwong serves as co-founder and chief development officer, while Dr. Maxime Ranger is CEO and chairman, guiding the company's focus on gut-restricted anti-inflammatories.[2][4] Early traction came from academic and venture support, including AmorChem as a founding investor, which spun out the technology from research programs.[3] A pivotal moment was the 2023 $11 million seed round, enabling preclinical advancement of lead candidate GT-2108 for ulcerative colitis.[4]
Giiant rides the wave of precision gastroenterology, where microbiome-targeted drug delivery addresses unmet needs in IBD amid rising prevalence driven by diet, genetics, and aging populations.[4][5] Timing aligns with advances in prodrug tech and microbiota research, amplified by post-pandemic focus on oral therapies over injectables for chronic GI conditions.[3][5] Market forces favor it: IBD affects millions globally with limited safe options, and gut-restricted delivery reduces toxicity risks, positioning Giiant to influence safer standards in a sector projected for growth via VC interest in localized biologics alternatives.[4] By partnering with funds like AmorChem and CQDM, it accelerates Quebec's biotech hub, fostering spinouts from academia into the global pharma pipeline.[3]
Giiant is primed to advance GT-2108 into clinical trials post-IND, potentially expanding its platform to broader GI diseases like Crohn's via microbiota bioactivation innovations.[4][5] Trends in AI-driven drug design and personalized microbiome therapies will shape its path, enhancing precision and scalability. Its influence may grow as a GI delivery pioneer, attracting big pharma partnerships and solidifying Montreal's role in biotech—echoing its origins in Merck-honed science to transform IBD care from systemic risks to targeted relief.[3][5]
Giiant Pharma has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Seed in May 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2021 | $12.0M Seed | Amplitude VC, Mott Family Capital, OrbiMed |